CN110831973B - 多特异性抗体及其制备和使用方法 - Google Patents

多特异性抗体及其制备和使用方法 Download PDF

Info

Publication number
CN110831973B
CN110831973B CN201880039401.4A CN201880039401A CN110831973B CN 110831973 B CN110831973 B CN 110831973B CN 201880039401 A CN201880039401 A CN 201880039401A CN 110831973 B CN110831973 B CN 110831973B
Authority
CN
China
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880039401.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831973A (zh
Inventor
朱义
欧勒·奥尔森
夏冬
大卫·耶利曼
卡特里娜·贝科娃
安妮玛丽·卢梭
比尔·布雷迪
布莱尔·伦肖
布莱恩·科瓦切维奇
梁玉
高泽人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Sichuan Baili Pharmaceutical Co Ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Bailidote Biological Pharmaceutical Co ltd, Sichuan Baili Pharmaceutical Co Ltd, Seattle Immunization Co filed Critical Chengdu Bailidote Biological Pharmaceutical Co ltd
Priority to CN202310141062.3A priority Critical patent/CN116041530A/zh
Priority to CN202310141321.2A priority patent/CN116199785A/zh
Priority to CN202310922275.XA priority patent/CN116948035A/zh
Publication of CN110831973A publication Critical patent/CN110831973A/zh
Application granted granted Critical
Publication of CN110831973B publication Critical patent/CN110831973B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880039401.4A 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法 Active CN110831973B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202310141062.3A CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141321.2A CN116199785A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310922275.XA CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202310922275.XA Division CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141321.2A Division CN116199785A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141062.3A Division CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Publications (2)

Publication Number Publication Date
CN110831973A CN110831973A (zh) 2020-02-21
CN110831973B true CN110831973B (zh) 2023-08-15

Family

ID=64742644

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201880039401.4A Active CN110831973B (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141321.2A Pending CN116199785A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310922275.XA Pending CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141062.3A Pending CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310141321.2A Pending CN116199785A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310922275.XA Pending CN116948035A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法
CN202310141062.3A Pending CN116041530A (zh) 2017-06-25 2018-06-22 多特异性抗体及其制备和使用方法

Country Status (10)

Country Link
US (1) US11787863B2 (https=)
EP (1) EP3645049A4 (https=)
JP (1) JP7399852B2 (https=)
KR (2) KR102763369B1 (https=)
CN (4) CN110831973B (https=)
AU (2) AU2018295118B2 (https=)
CA (1) CA3068045A1 (https=)
IL (2) IL313468A (https=)
SG (1) SG11201912864SA (https=)
WO (1) WO2019005639A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
US20250346681A1 (en) * 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531263A (ja) * 2001-05-11 2004-10-14 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
JP2008543339A (ja) * 2005-06-20 2008-12-04 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
CN101987871A (zh) * 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
CN104829733A (zh) * 2015-05-25 2015-08-12 广州科锐特生物科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
JP2016525551A (ja) * 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3060579A1 (en) * 2013-10-25 2016-08-31 Numab AG Bispecific constructs and their use in the treatment of various diseases
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531263A (ja) * 2001-05-11 2004-10-14 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
CN101987871A (zh) * 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
JP2008543339A (ja) * 2005-06-20 2008-12-04 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
JP2016525551A (ja) * 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
CN104829733A (zh) * 2015-05-25 2015-08-12 广州科锐特生物科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用

Also Published As

Publication number Publication date
CN116199785A (zh) 2023-06-02
KR102763369B1 (ko) 2025-02-05
CN116041530A (zh) 2023-05-02
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
AU2025204860A1 (en) 2025-07-17
NZ760913A (en) 2024-10-25
WO2019005639A2 (en) 2019-01-03
JP2020530777A (ja) 2020-10-29
KR20250024104A (ko) 2025-02-18
IL271257B1 (en) 2024-07-01
IL313468A (en) 2024-08-01
EP3645049A4 (en) 2021-06-30
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
US11787863B2 (en) 2023-10-17
EP3645049A2 (en) 2020-05-06
CN116948035A (zh) 2023-10-27
AU2018295118B2 (en) 2025-04-17
IL271257A (en) 2020-01-30
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
WO2019005639A3 (en) 2019-02-07
CA3068045A1 (en) 2019-01-03
RU2020102662A (ru) 2021-07-27
SG11201912864SA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
CN110831973B (zh) 多特异性抗体及其制备和使用方法
CN110799540B (zh) 多特异性抗体及其制备和使用方法
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
CN114026125B (zh) Cldn18.2抗体及其用途
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN113939536B (zh) Tigit和pd-1/tigit-结合分子
RU2730674C2 (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
CN110869390B (zh) 抗pd-l1抗体及其用途
CN101842116A (zh) 结合igf-1r多个表位的组合物
KR102558418B1 (ko) Pd-1에 결합하는 항체 및 그 용도
KR20220147642A (ko) Il4r에 결합하는 항체 및 이의 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
KR20220160555A (ko) Cd40에 결합하는 항체 및 이의 용도
AU2016330471A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
KR20160072268A (ko) 항-efna4 항체-약물 접합체
TW202313110A (zh) 癌症之治療
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
HK40018991B (zh) 多特异性抗体及其制备和使用方法
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
CN115667297B (zh) 结合il6r的抗体及其用途
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40019010B (zh) 多特异性抗体及其制备和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018991

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220607

Address after: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant after: Seattle Immunization Co.

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Address before: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant before: Seattle Immunization Co.

Applicant before: SICHUAN BAILI PHARM Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240623

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Patentee before: Seattle Immunization Co.

Country or region before: U.S.A.

Patentee before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China